Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin- treated DBA/2J mice

Timothy D. Wiggin, Matthias Kretzler, Subramaniam Pennathur, Kelli A. Sullivan, Frank C. Brosius, Eva L. Feldman

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Diabetic neuropathy (DN) is a common complication of diabetes. Currently, there is no drug treatment to prevent or slow the development of DN. Rosiglitazone (Rosi) is a potent insulin sensitizer and may also slow the development of DN by a mechanism independent of its effect on hyperglycemia. A two by two design was used to test the effect of Rosi treatment on the development of DN. Streptozotocin-induced diabetic DBA/2J mice were treated with Rosi. DN and oxidative stress were quantified, and gene expression was profiled using the Affymetrix Mouse Genome 430 2.0 microarray platform. An informatics approach identified key regulatory elements activated by Rosi. Diabetic DBA/2J mice developed severe hyperglycemia, DN, and elevated oxidative stress. Rosi treatment did not affect hyperglycemia but did reduce oxidative stress and prevented the development of thermal hypoalgesia. Two novel transcription factor binding modules were identified that may control genes correlated to changes in DN after Rosi treatment: SP1F_ZBPF and EGRF_EGRF. These targets may be useful in designing drugs with the same efficacy as Rosi in treating DN but with fewer undesirable effects.

Original languageEnglish (US)
Pages (from-to)4928-4937
Number of pages10
Issue number10
StatePublished - Oct 2008
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin- treated DBA/2J mice'. Together they form a unique fingerprint.

Cite this